Athersys, Inc. is an international biotechnology company that is focused in the field of regenerative medicine. They are committed to developing therapeutic products that they believe have best-in-class potential, meaning therapies that have the potential to be safer and more effective than the current standard of care or other products in development, and that may have other advantages, such as superior scalability or ease of administration.
Athersys is Developing the MultiStem Cell Therapy: MultiStem cell therapy, a patented and proprietary allogeneic “off-the-shelf” stem cell product, is our lead platform product and has shown promise for treating indications in the neurological, inflammatory and immune, and cardiovascular disease areas, as well as certain other critical care conditions. MultiStem is currently being evaluated in several clinical-stage programs.
Athersys' Business Strategy: Their principal business objective is to discover, develop and commercialize novel therapeutic products for disease indications that represent significant areas of clinical need and where they believe there is a substantial commercial opportunity.
Founding: Athersys was founded in 1995. They are headquartered in Cleveland, Ohio.
Industry: Business & Industrial > Pharmaceuticals & Biotech
More information about Athersys
|Address||StreetAddress: 3201 Carnegie Ave, AddressLocality: Cleveland, AddressRegion: Ohio, PostalCode: 44115, AddressCountry: United States|
|Number Of Employees||104|
|Ticker Symbol||NASDAQ: ATHX|
New York City, US
17 Sep 2023
Athersys (Biotechnology company)
Stock price : ATHX (NASDAQ) $0.30 -0.13 (-30.23%)Sep 15, 4:00 PM EDT - Disclaimer
Parent organization : ABT Holding Co
Headquarters : Cleveland, OH
Subsidiaries : ABT Holding Co, Advanced Biotherapeutics, Inc
Founded : 1995
Ceo : Daniel Camardo athersys.com